RSS

CVM Cel-Sci Corp.

Mod: mick
Last Post: 11/06/23
Followers: 1
Posts Today: 0
Views Today: 33

CVM Stock Quote & Tools

$1.7100 ▼ -0.0400 (-2.29%) As of Oct 14, 10:26 AM EDT
Last1.7100
$ Chg-0.0400
Open1.7300
High1.7500
Beta0.5886
Year High10.240
Market Cap30.08M
P/B Ratio3.11
EPS-1.03
Avg Vol (30d)234.7K
Volume16.2K
% Chg-2.29%
Prev Close1.7500
Low1.6800
VWAP1.70624
Year Low0.890
Total Shares17.59M
Shares Out17.59M
Float16.77M
ExchangeNYSE American
Healthcare Biotechnology & Life Sciences

CVM Stock Message Board Discussion

  1. mick

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Halozyme's Upcoming Investment Presentation at Healthcare Conference

Updated Category News Views 280

Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...

Continue Reading
Emerging Markets Surge Ahead with Historic Bond Sales Strategy

Updated Category News Views 241

Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...

Continue Reading
Multi Ways Holdings Reflects on Fiscal Year 2024 Performance

Updated Category News Views 167

Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...

Continue Reading
Neurocrine Adjusts Course Following Luvadaxistat Study Setback

Updated Category News Views 117

Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...

Continue Reading
Rinnai America Leads Coalition Against DOE Water Heater Rule

Updated Category News Views 294

Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...

Continue Reading